ClearDent Integrates Pearl Dental AI Platform

Pearl and ClearDent have announced a strategic partnership to integrate the Second Opinion radiologic dental AI platform into ClearDent’s practice management software. This collaboration aims to provide Canadian dental practitioners with advanced disease detection tools directly within their existing clinical workflows. By standardizing care and improving diagnostic accuracy, the integration represents a significant step forward in the adoption of artificial intelligence within the Canadian dental market.

Pearl, a global leader in dental AI, and ClearDent, a prominent Canadian dental software provider, have entered into a partnership to integrate Pearl’s Second Opinion disease detection software with ClearDent’s imaging toolset. Under ClearDent’s Developer Program, the Second Opinion software will be distributed to Canadian practices as an API-based integration before being transitioned into a native feature within the practice management platform. This move is designed to bring AI-assisted clinical care to a practitioner base that is recognized as one of the most technologically advanced in the world.

Pearl’s Second Opinion software is capable of detecting a wide array of dental pathologies, including caries, calculus, and periapical radiolucency. Through the new API integration, dentists can utilize these AI capabilities in real-time during clinical workflows, providing a more powerful lens for viewing radiographs and formulating diagnoses. Ophir Tanz, CEO of Pearl, stated that the partnership will markedly accelerate access to AI benefits, allowing clinicians to deliver higher-quality and more standardized care to their patients across Canada.

ClearDent has been a trusted provider of practice management solutions in Canada since 2002, offering a system that integrates scheduling, billing, and imaging while adhering to national regulatory and privacy standards. Karl Schmidt, Executive Vice President of Business Development at ClearDent, described the partnership as a logical step in helping the industry embrace innovative solutions to streamline practice operations. Pearl, founded in 2019, brings significant expertise to the table as the first company to receive FDA clearance for AI that identifies diseases in dental X-rays, with regulatory clearances now spanning 120 countries.

The collaboration will extend beyond software integration to include joint educational initiatives, such as webinars and events, aimed at advancing the adoption of AI in everyday clinical practice. With Second Opinion already cleared for use in major markets including the USA, Europe, Australia, and New Zealand, this partnership reinforces the global trend of utilizing computer vision to enhance patient health outcomes. The initiative is expected to build greater trust in dental medicine by providing practitioners with robust, accessible tools for precise clinical decision-making.